Key Developments: Galapagos NV (GLPYY.PK)

GLPYY.PK on OTC Markets Group

13.99USD
3:41pm EDT
Price Change (% chg)

$-0.30 (-2.08%)
Prev Close
$14.29
Open
$14.00
Day's High
$14.00
Day's Low
$13.93
Volume
800
Avg. Vol
1,210
52-wk High
$25.04
52-wk Low
$12.91

Search Stocks

Latest Key Developments (Source: Significant Developments)

Galapagos NV and Calchan Limited collaborate on osteoarthritis research, 2.4 million pounds grant awarded by Innovate UK
Monday, 27 Oct 2014 02:39am EDT 

Galapagos NV:Says that the company and Calchan Limited, UK company focused on the development of medicines based on calcium ion channel modulators, announce that they have entered into research collaboration in area of osteoarthritis pain.Calchan has been awarded 2.4 million pounds grant from Innovate UK, UK's innovation agency, Biomedical Catalyst Early Stage Round 2to discover and develop compounds against novel target for osteoarthritic pain.Calchan and Galapagos will collaborate in identifying pre-clinical candidates.Subsequently, Calchan and Galapagos may jointly progress assets further into clinic.Further financial details remain undisclosed.  Full Article

Galapagos announces favorable data for phase 1 inflammatory bowel disease drug
Monday, 20 Oct 2014 01:30am EDT 

Galapagos NV:Announces novel target and presents favorable phase 1 data for GLPG1205.Says GPR84 is promising novel target for treating inflammatory bowel disease.Says GLPG1205 shows strong efficacy in relevant pre-clinical models for IBD.  Full Article

Bart Filius joins Galapagos NV as CFO
Wednesday, 15 Oct 2014 01:33am EDT 

Galapagos NV:Says that Bart Filius, will join Galapagos as Chief Financial Officer, effective Dec. 1, 2014.  Full Article

Galapagos presents cystic fibrosis combination therapy
Thursday, 9 Oct 2014 01:30am EDT 

Galapagos NV:Presents cystic fibrosis combination therapy at North American Cystic Fibrosis Conference in Atlanta.Presents a poster disclosing discovery process for complementary corrector series that restore CFTR function in a new way.Corrector series in combination with potentiator GLPG1837, and GLPG1837 and corrector C18, restore >40 pct of healthy function in cells with the mutation DELF508.Plans to enter phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before the end of 2014.  Full Article

Galapagos NV announces increase of number of outstanding ordinary shares
Wednesday, 24 Sep 2014 08:00pm EDT 

Galapagos NV:Announces that 12,260 new ordinary shares issued by the company, immediately assimilated with the existing ordinary shares, will be listed on the market Euronext Amsterdam as of Sep. 29.Says the old number of outstanding shares is 30,280,344.Says the number of shares to be listed is 12,260.Says the new number of outstanding shares is 30,292,604.Says the reason is for exercise of option.  Full Article

Galapagos initiates Phase 1 study with GLPG1690
Tuesday, 1 Jul 2014 01:31am EDT 

Galapagos NV:GLPG1690 molecule aimed at treating pulmonary diseases dosed in Phase 1 First-in-Human study.Company to receive 6.6 mln euros milestone payment from Janssen Pharmaceutica NV for this achievement.Phase 1 study aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1690.Randomized, double-blind, placebo-controlled, single center study is being conducted in at least 40 healthy volunteers in Belgium.  Full Article

Galapagos updates on products clinical trials
Tuesday, 17 Jun 2014 01:39am EDT 

Galapagos NV:Highlights progress and plans for its R&D program portfolio.Selective JAK1 inhibitor GLPG0634 shows positive profile in two rheumatoid arthritis Phase 2 studies.GLPG0634 is being trialled in global Phase 2b program (DARWIN) in 875 rheumatoid arthritis patients and Phase 2 study in 180 patients with Crohn's disease.GLPG0974 selective antagonist of FFA2 is to be tested in clinic.Four-week Phase 2 proof-of-concept study recently completed with GLPG0974 in 45 ulcerative colitis (UC) patients in 16 centers in four European countries.Multiple series of correctors showing better activity than VX-809 in pre-clinical tests in f508del mutation with GLPG1837 discovered by company and its partner AbbVie.Narrow spectrum antibiotic GLPG1492 expected to be dosed in first volunteers (Phase 1) in H2 2014.  Full Article

Galapagos NV announces management change
Monday, 28 Apr 2014 01:34am EDT 

Galapagos NV:Says Guillaume Jetten will resign as Chief Financial Officer of Galapagos, effective May 1.Laure Verhaegen, Vice President Finance, will act as interim CFO until a replacement has been recruited.  Full Article

Galapagos says GSK2586184 met primary endpoint in Phase 2a psoriasis study
Thursday, 17 Apr 2014 01:01am EDT 

Galapagos NV:Says GSK2586184 met primary endpoint in Phase 2a psoriasis study.Study JAK116679 was phase 2a multi-centre, randomised, double-blind, placebo-controlled, dose ranging study (100mg bid, 200mg bid, 400mg bid) that evaluated safety and efficacy of GSK2586184 compared with placebo in 66 patients with chronic plaque psoriasis.Preliminary results showed that significantly higher proportion of patients treated with GSK2586184 at 400mg bid dose met primary endpoint compared to placebo.Primary endpoint was defined as achieving >=75 pct improvement from baseline in Psoriasis Area Severity Index (PASI75) score at week 12.PASI75 for patients randomised to placebo was in range expected.During treatment period most common adverse events occurring with frequency of more than 20 pct on either placebo or pooled GSK2586184 were headache (36 pct placebo, 27 pct GSK2586184) and nasopharyngitis (21 pct placebo, 29 pct GSK2586184).  Full Article

Galapagos NV completes sale of BioFocus and Argenta service to Charles River Laboratories
Tuesday, 1 Apr 2014 01:45am EDT 

Galapagos NV:Confirms the completion of the transaction announced on March 13, 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc.Total consideration of up to 134 million euros.  Full Article

Belgium's Galapagos hires Sanofi Europe exec as new CFO

BRUSSELS, Oct 15 - Belgian biotech group Galapagos said on Wednesday that it had hired Bart Filius, vice president of Sanofi Europe, as its new chief financial officer.

No consensus analysis data available.
Search Stocks